Petros Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Petros Pharmaceuticals, Inc.
Deal Watch: Roche And Vividion Will Investigate E3 Ligases In Cancer, Immunology
Also, news on transactions involving Neurocrine/Idorsia, Neurotrope/Metuchen, jCyte/Santen, PTC/Censa, Hoth/Chelexa, Skyhawk/Merck & Co., Orexo/Gaia, Karo/J&J, MaxCyte/Caribou, Mediolanum/ElsaLys, Avectas/ONK
YouTube Video Suggesting Livalo Is Safer Than Other Statins Is Dinged By US FDA
Kowa Pharmaceuticals' patient testimonials implying switch from statins to Livalo will reduce drug side effects are misleading, untitled letter says.
Warning Letter: New Sponsor, Same Violative Promotional Practices For Insomnia Drug Doral
An OPDP warning letter hits Galt Pharmaceuticals for misbranding its insomnia drug Doral with similar to concerns to those outlined in a 2014 untitled letter to the then-sponsor Sciecure.
US FTC Calls Out Personal Injury Rx Ads As Potentially Misleading
The US Federal Trade Commission says the ads may be causing patients to stop taking medications, asks that they include scientifically sound information and be careful using scare tactics.
- Specialty Pharmaceuticals
- Surgical Equipment & Devices
- Other Names / Subsidiaries
- Metuchen Pharmaceuticals LLC
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.